DNA vaccines against foot-and-mouth disease virus
AssigneeThe Government of the United States of America, as represented by the Secretary of Homeland Security
InventorsMichael Puckette, Max V. Rasmussen
Life of this patent
Estimating the term…
Abstract
This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
Claims23
A DNA vaccine against foot-and-mouth disease virus (FMDV), comprising:
- a polynucleotide encoding a FMDV P1 precursor polypeptide;
- and
- a polynucleotide encoding a modified FMDV 3C protease, wherein the modified FMDV 3C protease comprises a L127 amino acid substitution of a wild-type FMDV 3C protease.
A pharmaceutical composition, comprising:
- a polynucleotide encoding a FMDV P1 precursor polypeptide,
- a polynucleotide encoding a modified FMDV 3C protease, wherein the modified FMDV 3C protease comprises a L127 amino acid substitution of a wild-type FMDV 3C protease;
- and
- a pharmaceutically acceptable carrier.
A method for inducing an immune response against foot-and-mouth disease virus (FMDV) in a subject, vaccinating a subject against FMDV, or reducing severity of an FMDV infection in a subject, comprising administering to said subject an effective amount of a composition comprising:
- a polynucleotide encoding a FMDV P1 precursor polypeptide;
- and
- a polynucleotide encoding a modified FMDV 3C protease, wherein the modified FMDV 3C protease comprises a L127 amino acid substitution of a wild-type FMDV 3C protease, wherein the FMDV P1 precursor polypeptide is expressed and proteolytically processed by the co-expressed modified FMDV 3C protease.
Dependencies are inferred from the claim text.